Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France
France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/21645515.2024.2387221 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850185069005635584 |
|---|---|
| author | Paul Loubet Benjamin Gaborit Mathilde Salpin Hèlene Gardeney Ilies Benotmane Thomas Systchenko |
| author_facet | Paul Loubet Benjamin Gaborit Mathilde Salpin Hèlene Gardeney Ilies Benotmane Thomas Systchenko |
| author_sort | Paul Loubet |
| collection | DOAJ |
| description | France was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported. |
| format | Article |
| id | doaj-art-1e33f7c4698e4801b92f13b3d35ed9e6 |
| institution | OA Journals |
| issn | 2164-5515 2164-554X |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj-art-1e33f7c4698e4801b92f13b3d35ed9e62025-08-20T02:16:50ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2024-12-0120110.1080/21645515.2024.2387221Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in FrancePaul Loubet0Benjamin Gaborit1Mathilde Salpin2Hèlene Gardeney3Ilies Benotmane4Thomas Systchenko5Virulence Bactérienne et Infections Chroniques, University Montpellier, Nîmes, FranceService des Maladies Infectieuses et Tropicales, CHU Nantes, Nantes, FranceService de Pneumologie, AP-HP, Hôpital Bichat, Paris, FranceService d’Hématologie, CHU Poitiers, Poitiers, FranceService de Néphrologie-Dialyse-Transplantation, CHU Strasbourg, Strasbourg, FranceService d’Hématologie, CHU Poitiers, Poitiers, FranceFrance was the first country to grant Sipavibart (AZD3152, an investigational long-acting monoclonal antibody) as a COVID-19 pre-exposure prophylaxis treatment in immunocompromised individuals in December 2023. The first patients to receive Sipavibart had different profiles, but they were all highly immunocompromised with frequently associated hypogammaglobulinemia and other chronic conditions. No adverse event was reported.https://www.tandfonline.com/doi/10.1080/21645515.2024.2387221COVID-19prophylaxisimmunocompromised |
| spellingShingle | Paul Loubet Benjamin Gaborit Mathilde Salpin Hèlene Gardeney Ilies Benotmane Thomas Systchenko Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France Human Vaccines & Immunotherapeutics COVID-19 prophylaxis immunocompromised |
| title | Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France |
| title_full | Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France |
| title_fullStr | Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France |
| title_full_unstemmed | Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France |
| title_short | Characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for COVID-19 pre-exposure prophylaxis in France |
| title_sort | characteristics of the first immunocompromised patients to receive sipavibart as an early access treatment for covid 19 pre exposure prophylaxis in france |
| topic | COVID-19 prophylaxis immunocompromised |
| url | https://www.tandfonline.com/doi/10.1080/21645515.2024.2387221 |
| work_keys_str_mv | AT paulloubet characteristicsofthefirstimmunocompromisedpatientstoreceivesipavibartasanearlyaccesstreatmentforcovid19preexposureprophylaxisinfrance AT benjamingaborit characteristicsofthefirstimmunocompromisedpatientstoreceivesipavibartasanearlyaccesstreatmentforcovid19preexposureprophylaxisinfrance AT mathildesalpin characteristicsofthefirstimmunocompromisedpatientstoreceivesipavibartasanearlyaccesstreatmentforcovid19preexposureprophylaxisinfrance AT helenegardeney characteristicsofthefirstimmunocompromisedpatientstoreceivesipavibartasanearlyaccesstreatmentforcovid19preexposureprophylaxisinfrance AT iliesbenotmane characteristicsofthefirstimmunocompromisedpatientstoreceivesipavibartasanearlyaccesstreatmentforcovid19preexposureprophylaxisinfrance AT thomassystchenko characteristicsofthefirstimmunocompromisedpatientstoreceivesipavibartasanearlyaccesstreatmentforcovid19preexposureprophylaxisinfrance |